Product Description
SUMO2/3 Antibody [S23MT-1] | 33-933 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Recombinant human SUMO2 protein was used as the immunogen for this SUMO2/3 antibody. This antibody reacts with both SUMO2 and SUMO3.
Research Area: Neuroscience, Signal Transduction
Tested Application: WB, IHC, IF
Application: IF: 0.5-1 ug/ml
WB: 0.5-1 ug/ml
IHC (FFPE) : 0.5-1 ug/ml for 30 minutes at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Titering of the SUMO2/3 antibody may be required for optimal performance.
1. FFPE testing requires sections to be boiled in pH6 10mM citrate buffer for 10-20 minutes, followed by cooling at RT for 20 minutes, prior to staining.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G purified
Clonality: Monoclonal
Clone: S23MT-1
Isotype: IgG1, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: N/A
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer’s disease.